To the Editor The recently published Original Investigation by Lintzeris and colleagues1 about nabiximols for the treatment of cannabis dependence reported that cannabinoid agonist medication reduces illicit cannabis use among cannabis-dependent persons. We have some concerns about how the authors represented their data, leading us to believe that such a conclusion is not justified. The authors appear to have switched primary outcomes between study registration and publication, thereby inaccurately portraying the trial results.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kleinman RA, Ostacher MJ. Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence. JAMA Intern Med. 2020;180(1):163. doi:10.1001/jamainternmed.2019.5667
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: